Article
A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).
Thoracic cancer - 1 Dec 2022
Choi Juwhan, Lee Jeong Eun, Choi Chang-Min, Oh In-Jae, Lee Kye Young, Jang Tae Won, Lee Seung Hyeun, Kim Eun Young, Park Dong Won, Park Sun Hyo, Lee Sung Yong
Abstract excerpt
INTRODUCTION: The PACIFIC study demonstrated that durvalumab consolidation therapy significantly improved progression-free survival (PFS) and overall survival (OS) in patients with unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CCRT). However, there was no clinical benefit in both PFS and OS in epidermal growth factor receptor (EGFR) mutation-positive patient groups...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.